rais target price
manag track exceed
improv organ growth support strong pipelin new product
remain track meet exceed organ growth guidanc driven
improv execut new product compani result organ growth
de-risk compani outlook take pressur
creat potenti upsid addit expect compani end
solid head steam array new recent launch product expect
drive continu growth reiter outperform rais
target price
pipelin track drive beyond expect org growth
better in-lin manag guidanc acceler growth
driven part low-risk tavr launch approv next-gen evolut
robot spine surgeri mazorx minim hybrid close loop system
next-gen intelli addit expect new product launch carri
follow fiscal year beyond posit meet exceed long-
run growth target
incom ceo potenti catalyst impress geoff martha
record execut restor therapi group see appoint ceo
end opportun drive improv perform across compani
busi line well term background rtg growth rate improv
end mr martha tenur driven larg part
new product launch acquisit includ mazor robot surgeri system
valuat target price prev base ebitda multipl
ntm ebitda estim bil one year forward unch
multipl roughli line mdt current multipl risk product delay
failur progress long-term goal growth margin potenti new litig
regulatori qualiti issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag januari
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
medtron plc global manufactur provid medic devic
equip area cardiac rhythm manag vascular
intervent structur valvular diseas spinal disord
neuromodul surgic equip diabet
one-year valuat scenario base
ev/ebitda ntm ebitda estim bil
one year forward scenario base emerg segment
deliv growth high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ntm ebitda estim bil
one year forward grey scenario base emerg segment
deliv growth high-growth segment grow
growth grow
 close
mariu zoican univers toronto rotman school manag januari
target price base ebitda multipl ntm ebitda estim
bil one year forward multipl roughli line mdt current trade
multipl reflect robust product pipelin broad market footprint global reach
posit deliv sustain growth double-digit total sharehold return
attract portfolio emerging- high-growth busi
highlight mdt key product launch figur see low-risk tavr micra av
leadless pacer reveal linq insert monitor robot spine surgeri
major driver anoth potenti come behind growth driver shown figur
pull-through tyrx anti-infect growth share driven wrap-it trial data
present last year despit tepid respons street continu view
result random multi-cent studi potenti drive
reimburs guidelin chang
figur recent upcom product launch
yr sd vs yr mariu zoican univers toronto rotman school manag januari
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
